Compare NEOG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | MLYS |
|---|---|---|
| Founded | 1981 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1995 | 2023 |
| Metric | NEOG | MLYS |
|---|---|---|
| Price | $9.60 | $27.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $10.67 | ★ $48.67 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 04-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $894,661,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | $458.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.32 | $12.59 |
| 52 Week High | $11.43 | $47.65 |
| Indicator | NEOG | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 53.22 |
| Support Level | $8.93 | $26.85 |
| Resistance Level | $10.30 | $31.09 |
| Average True Range (ATR) | 0.52 | 1.65 |
| MACD | 0.07 | 0.38 |
| Stochastic Oscillator | 44.32 | 62.11 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.